FDA inspection
GlaxoSmithKline Biologicals SA: FDA inspection ending Feb 27, 2026
FDA inspection 1304664 · Rixensart
Key facts
| Inspection ID | 1304664 |
|---|---|
| Firm | GlaxoSmithKline Biologicals SA |
| FEI number | 3002875226 |
| Address | Rue De L'Institut 89 |
| City | Rixensart |
| Fiscal year | 2026 |
| Inspection end date | Feb 27, 2026 |
| Project area | Vaccine, Allergenic, and Live Biotherapeutic Products |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data